%20BIOSCIENCE%20CO.%2C%20LTD./other/MABWELL_SHANGHAI_BIOSCIENCE_CO._LTD.-logo.png){kind=logo}
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings
Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 北京植德（上海）律师事务所关于迈威（上海）生物科技股份有限公司2026年第二次临时股东会的法律意见书 | 2026-06-01 | Chinese | |
| 迈威生物2026年第三次临时股东会会议资料 | 2026-06-01 | Chinese | |
| 迈威生物2026年第二次临时股东会决议公告 | 2026-06-01 | Chinese | |
| 迈威生物关于新增认定核心技术人员的公告 | 2026-05-29 | Chinese | |
| 迈威生物关于公司董事会换届选举的公告 | 2026-05-29 | Chinese | |
| 迈威生物独立董事提名人声明与承诺（秦正余） | 2026-05-29 | Chinese |
Browse filings by year
6 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 47926709 | 北京植德（上海）律师事务所关于迈威（上海）生物科技股份有限公司2026年第二次临时股东会的法律意见书 | 2026-06-01 | Chinese | ||
| 47926229 | 迈威生物2026年第三次临时股东会会议资料 | 2026-06-01 | Chinese | ||
| 47926168 | 迈威生物2026年第二次临时股东会决议公告 | 2026-06-01 | Chinese | ||
| 47897926 | 迈威生物关于新增认定核心技术人员的公告 | 2026-05-29 | Chinese | ||
| 47897903 | 迈威生物关于公司董事会换届选举的公告 | 2026-05-29 | Chinese | ||
| 47897902 | 迈威生物独立董事提名人声明与承诺（秦正余） | 2026-05-29 | Chinese | ||
| 47897693 | 迈威生物第二届董事会第三十三次会议决议公告 | 2026-05-29 | Chinese | ||
| 47897691 | 董事、高级管理人员薪酬管理制度 | 2026-05-29 | Chinese | ||
| 47897689 | 迈威生物关于召开2026年第三次临时股东会的通知 | 2026-05-29 | Chinese | ||
| 47897688 | 迈威生物独立董事提名人声明与承诺（李凡） | 2026-05-29 | Chinese | ||
| 47897686 | 迈威生物独立董事提名人声明与承诺（王芳） | 2026-05-29 | Chinese | ||
| 47897685 | 迈威生物独立董事提名人声明与承诺（周睿） | 2026-05-29 | Chinese | ||
| 47897682 | 迈威生物独立董事候选人声明与承诺（李凡） | 2026-05-29 | Chinese | ||
| 47897095 | 迈威生物独立董事候选人声明与承诺（秦正余） | 2026-05-29 | Chinese | ||
| 47897093 | 迈威生物独立董事候选人声明与承诺（周睿） | 2026-05-29 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
CORCEPT THERAPEUTICS INC
Develops and commercializes cortisol-modulating medications…
|
CORT | US | Manufacturing |
|
Corline Biomedical AB
Develops heparin-based solutions for medical devices and re…
|
CLBIO | SE | Manufacturing |
|
CorMedix Inc.
Biopharma firm developing therapeutics for infectious and i…
|
CRMD | US | Manufacturing |
|
Corona Remedies Limited
Develops and manufactures therapeutic solutions across dive…
|
CORONA | IN | Manufacturing |
|
Corvus Pharmaceuticals, Inc.
Clinical-stage biopharma developing therapies for immune di…
|
CRVS | US | Manufacturing |
|
COSCIENS Biopharma Inc.
Develops and commercializes natural-based active ingredient…
|
CSCI | CA | Manufacturing |
|
Cosma Spolka Akcyjna
Manufactures and distributes hemp and cannabis products for…
|
COS | PL | Manufacturing |
|
COSMO Pharmaceuticals N.V.
A specialty pharmaceutical firm focused on gastroenterology…
|
COPN | NL | Manufacturing |
|
Cosmos Health Inc.
Vertically integrated healthcare group in the nutraceutical…
|
COSM | US | Manufacturing |
|
Cotinga Pharmaceuticals Inc.
Clinical-stage biopharma developing AI-driven therapeutics …
|
COT | CA | Manufacturing |
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58111/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58111 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58111 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58111 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58111}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. (id: 58111)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.